CatalYm Trial Targets Liver Cancer's Immune Shield and Wasting Effects

MUNICH & SAN FRANCISCO – April 07, 2026 – Biotechnology firm CatalYm has initiated a pivotal clinical trial that could offer new hope for patients with advanced liver cancer, a disease notoriously difficult to treat. The company announced the first patient has been dosed in its Phase 2b study, evaluating a novel drug, visugromab, designed to dismantle a dual-pronged defense mechanism that tumors use to survive and grow.

The trial, named GDFATHER-HCC-01, targets patients with unresectable or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. It specifically focuses on a population with dire prognoses: those whose disease has progressed despite treatment with modern first-line immunotherapies. By combining visugromab with established cancer therapies, CatalYm aims to break through treatment resistance and address one of oncology's most significant challenges.

An Urgent Need in Advanced Liver Cancer

Hepatocellular carcinoma is a global health crisis, ranking as the third leading cause of cancer-related deaths worldwide. The prognosis for patients with advanced disease is bleak, with a five-year survival rate hovering at a grim 18%, one of the lowest among common cancers.

While the advent of immune checkpoint inhibitors (ICIs) like anti-PD-1 therapies has revolutionized first-line treatment, their success is often temporary. A majority of patients eventually see their tumors adapt, progress, or relapse. Once this happens, they face a landscape of limited and often modestly effective second-line options, primarily consisting of tyrosine kinase inhibitors (TKIs) like regorafenib and cabozantinib.

“HCC is the third leading cause of cancer-related deaths globally and continues to present immense clinical challenges, especially in patients who progress on immunotherapy,” said Sujata Rao, MD, Chief Medical Officer at CatalYm, in the company's announcement. This gap in care creates a substantial and growing patient population in desperate need of new therapeutic strategies.

The Dual Threat of GDF-15

CatalYm’s strategy hinges on neutralizing a protein called Growth Differentiation Factor-15 (GDF-15). In healthy individuals, GDF-15 is a stress-response cytokine. In the context of cancer, however, many tumors overproduce it, turning the protein into a powerful tool for self-preservation.

GDF-15 acts as a cloaking device, creating an immunosuppressive shield around the tumor. It actively prevents the body’s T-cells—the primary soldiers of the immune system—from infiltrating and attacking the cancer cells. This mechanism is a key reason why treatments like anti-PD-1, which are designed to unleash T-cells, can fail. High levels of GDF-15 are correlated with resistance to immunotherapy and poor patient outcomes across multiple tumor types.

Furthermore, GDF-15 is a primary driver of cancer cachexia, a debilitating wasting syndrome characterized by severe muscle loss, fatigue, and loss of appetite. Cachexia affects nearly one in four HCC patients at diagnosis and profoundly diminishes their quality of life, tolerance to treatment, and overall survival.

Visugromab is a monoclonal antibody engineered to find and neutralize GDF-15. The hypothesis is that by taking GDF-15 out of commission, visugromab can achieve two critical goals simultaneously: tear down the tumor's immune shield to re-sensitize it to immunotherapy and, at the same time, alleviate the devastating effects of cachexia.

Encouraging data from CatalYm's earlier Phase 1/2a GDFATHER trial, published in the prestigious journal Nature, showed that this approach holds significant promise. In a cohort of heavily pretreated HCC patients who had relapsed on immunotherapy, the combination of visugromab and an anti-PD-1 antibody produced deep and durable responses, with a remarkable median duration of response of 21.4 months.

A Triple-Combination Strategy

The new GDFATHER-HCC-01 trial aims to build on this foundation with a potent triple-combination therapy. The study will evaluate visugromab alongside two current standards of care: the PD-1 inhibitor nivolumab and the multi-target TKI lenvatinib. This multi-pronged attack is designed to simultaneously block the GDF-15 shield, reinvigorate the anti-tumor immune response, and inhibit pathways that fuel tumor growth.

The global, randomized, and double-blind study will enroll approximately 104 participants across 40 sites in North America, Europe, and the Asia-Pacific region. Its primary goal is to determine if the triple combination can extend progression-free survival. Crucially, the trial will also track key secondary endpoints, including overall survival and objective response rate. It will also formally assess visugromab’s impact on cachexia using a specialized patient questionnaire, a novel endpoint that underscores the drug's unique dual mechanism.

“Expanding into HCC represents a pivotal step in our strategy to bring visugromab to additional high-need tumor types,” said Scott Clarke, Chief Executive Officer at CatalYm. “By combining our antibody with proven standards of care, we aim to shift the treatment paradigm and ultimately improve survival and quality of life for patients who have few options today.”

Market Confidence and Strategic Vision

CatalYm's ambitious clinical program is backed by significant investor confidence. The company, founded in 2016, has successfully raised over $260 million, including a recent $150 million Series D financing round led by prominent life-science investors like Canaan Partners, Forbion, and Novartis Venture Fund. This financial backing is crucial for funding the expensive, late-stage trials needed for drug approval.

The potential market is substantial. The global market for HCC drugs is projected to grow from around $4 billion today to nearly $10 billion by 2032, driven by the high incidence of the disease and the urgent need for better therapies. While other companies, such as Pfizer, are also exploring GDF-15 inhibitors, their primary focus has been on cachexia. CatalYm’s strategy of integrating the anti-cancer and anti-cachexia benefits into a core oncology treatment gives it a unique position in the competitive landscape.

With parallel Phase 2b trials for visugromab also underway in non-small cell lung cancer (NSCLC), CatalYm is making a major bet that neutralizing GDF-15 is a foundational new pillar of cancer therapy. For thousands of liver cancer patients who have run out of options, the progress of the GDFATHER-HCC-01 trial will be watched with intense anticipation.